High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells

BMC Biotechnology

Volumn 13, Issue , 2013, Pages

  Jäger, Volker ^a   Büssow, Konrad ^a   Wagner, Andreas ^a   Weber, Susanne ^b   Hust, Michael ^b   Frenzel, André ^b   Schirrmann, Thomas ^b  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

ImmunoRNase; Recombinant Antibodies; scFv Fc; Serum free medium; Single Chain Fv; Transient Mammalian Protein Production

Indexed keywords

IMMUNORNASE; MAMMALIAN PROTEINS; RECOMBINANT ANTIBODY; SCFV-FC; SERUM-FREE MEDIUM; SINGLE-CHAIN FV;

BODY FLUIDS; CELLS; CYTOLOGY; GENE EXPRESSION; MAMMALS; MONOCLONAL ANTIBODIES; OPTIMIZATION; RECOMBINANT PROTEINS; THROUGHPUT; VIRUSES;

CHEMICAL DETECTION;

EPSTEIN BARR VIRUS ANTIGEN 1; HYBRID PROTEIN; IMMUNOGLOBULIN G; RECOMBINANT ANTIBODY; RIBONUCLEASE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY PRODUCTION; ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CONTROLLED STUDY; EXPRESSION VECTOR; FED BATCH CULTURE; GENE LIBRARY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PHAGE DISPLAY; PROTEIN EXPRESSION; SUSPENSION;

CLONING, MOLECULAR; GENETIC VECTORS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; PEPTIDE LIBRARY; RECOMBINANT FUSION PROTEINS; RIBONUCLEASES; SINGLE-CHAIN ANTIBODIES;

HUMAN HERPESVIRUS 4; MAMMALIA;

EID: 84879446443     PISSN: None     EISSN: 14726750     Source Type: Journal    
DOI: 10.1186/1472-6750-13-52     Document Type: Article

References (61)

1. Taussig MJ, Stoevesandt O, Borrebaeck CAK, Bradbury AR, Cahill D, Cambillau C, de Daruvar A, Dübel S, Eichler J, Frank R, Gibson TJ, Gloriam D, Gold L, Herberg FW, Hermjakob H, Hoheisel JD, Joos TO, Kallioniemi O, Koegl M, Koegll M, Konthur Z, Korn B, Kremmer E, Krobitsch S, Landegren U, van der Maarel S, McCafferty J, Muyldermans S, Nygren P-A, Palcy S, Plückthun A, Polic B, Przybylski M, Saviranta P, Sawyer A, Sherman DJ, Skerra A, Templin M, Ueffing M, Uhlén M. ProteomeBinders: planning a European resource of affinity reagents for analysis of the human proteome. Nat Methods 2007, 4:13-17. 10.1038/nmeth0107-13, 17195019.
2. Dübel S, Stoevesandt O, Taussig MJ, Hust M. Generating recombinant antibodies to the complete human proteome. Trends Biotechnol 2010, 28:333-339. 10.1016/j.tibtech.2010.05.001, 20538360.
3. Colwill K, Gräslund S. A roadmap to generate renewable protein binders to the human proteome. Nat Methods 2011, 8:551-558. 10.1038/nmeth.1607, 21572409.
4. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, Kirsch MI, Schütte M, Helmsing S, Meier D, Schirrmann T, Dübel S. A human scFv antibody generation pipeline for proteome research. J Biotechnol 2011, 152:159-170. 10.1016/j.jbiotec.2010.09.945, 20883731.
5. Hust M, Steinwand M, Al-Halabi L, Helmsing S, Schirrmann T, Dübel S. Improved microtitre plate production of single chain Fv fragments in Escherichia coli. N Biotechnol 2009, 25:424-428. 10.1016/j.nbt.2009.03.004, 19552889.
6. Shu L, Qi CF, Schlom J, Kashmiri SV. Secretion of a single-gene-encoded immunoglobulin from myeloma cells. PNAS 1993, 90:7995-7999. 10.1073/pnas.90.17.7995, 47274, 8367454.
7. Moutel S, El Marjou A, Vielemeyer O, Nizak C, Benaroch P, Dübel S, Perez F. A multi-Fc-species system for recombinant antibody production. BMC Biotechnol 2009, 9:14. 10.1186/1472-6750-9-14, 2654441, 19245715.
8. Thie H, Toleikis L, Li J, von Wasielewski R, Bastert G, Schirrmann T, Esteves IT, Behrens CK, Fournes B, Fournier N, de Romeuf C, Hust M, Dübel S. Rise and fall of an anti-MUC1 specific antibody. PLoS One 2011, 6:e15921. 10.1371/journal.pone.0015921, 3021526, 21264246.
9. Kirsch MI, Hülseweh B, Nacke C, Rülker T, Schirrmann T, Marschall H-J, Hust M, Dübel S. Development of human antibody fragments using antibody phage display for the detection and diagnosis of Venezuelan equine encephalitis virus (VEEV). BMC Biotechnol 2008, 8:66. 10.1186/1472-6750-8-66, 2543005, 18764933.
10. Girgis MD, Olafsen T, Kenanova V, McCabe KE, Wu AM, Tomlinson JS. Targeting CEA in pancreas cancer xenografts with a Mutated scFv-Fc antibody fragment. EJNMMI Res 2011, 1:24. 10.1186/2191-219X-1-24, 3251041, 22214289.
11. Menzel C, Schirrmann T, Konthur Z, Jostock T, Dübel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood 2008, 111:3830-3837. 10.1182/blood-2007-04-082768, 18230757.
12. Shen Z, Stryker GA, Mernaugh RL, Yu L, Yan H, Zeng X. Single-chain fragment variable antibody piezoimmunosensors. Anal Chem 2005, 77:797-805. 10.1021/ac048655w, 2505340, 15679346.
13. Al-Halabi L, Balck A, Michalzik M, Fröde D, Büttgenbach S, Hust M, Schirrmann T, Dubel S. Recombinant antibody fragments allow repeated measurements of C-reactive protein with a quartz crystal microbalance immunosensor. MAbs 2013, 5:0-1.
14. Pohl SC, Schwarz S, Frenzel A, Schirrmann T. A cassette vector system for the rapid cloning and production of bispecific tetravalent antibodies. Antibodies 2012, 1:19-38.
15. Schirrmann T, Pecher G. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Cancer Gene Ther 2002, 9:390-398. 10.1038/sj.cgt.7700453, 11960290.
16. Schirrmann T, Pecher G. Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor. Leuk Res 2005, 29:301-306. 10.1016/j.leukres.2004.07.005, 15661266.
17. Capodicasa C, Chiani P, Bromuro C, De Bernardis F, Catellani M, Palma AS, Liu Y, Feizi T, Cassone A, Benvenuto E, Torosantucci A. Plant production of anti-β-glucan antibodies for immunotherapy of fungal infections in humans. Plant Biotechnol J 2011, 9:776-787. 10.1111/j.1467-7652.2010.00586.x, 21265996.
18. Rülker T, Voß L, Thullier P, O' Brien LM, Pelat T, Langermann C, Schirrmann T, Dübel S, Marschall H-J, Hust M, Hülseweh B. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV In Vitro and In Vivo. PLoS One 2012, 7:e37242. 10.1371/journal.pone.0037242, 3364240, 22666347.
19. West AP, Galimidi RP, Gnanapragasam PNP, Bjorkman PJ. Single-chain Fv-based anti-HIV proteins: potential and limitations. J Virol 2012, 86:195-202. 10.1128/JVI.05848-11, 3255864, 22013046.
20. Liu J, Wei D, Qian F, Zhou Y, Wang J, Ma Y, Han Z. pPIC9-Fc: a vector system for the production of single-chain Fv-Fc fusions in Pichia pastoris as detection reagents in vitro. J Biochem 2003, 134:911-917. 10.1093/jb/mvg222, 14769881.
21. Zhang N, Liu L, Dumitru CD, Cummings NRH, Cukan M, Jiang Y, Li Y, Li F, Mitchell T, Mallem MR, Ou Y, Patel RN, Vo K, Wang H, Burnina I, Choi B-K, Huber HE, Stadheim TA, Zha D. Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. MAbs 2011, 3:289-298. 10.4161/mabs.3.3.15532, 3149709, 21487242.
22. Ye J, Ly J, Watts K, Hsu A, Walker A, McLaughlin K, Berdichevsky M, Prinz B, Sean Kersey D, d' Anjou M, Pollard D, Potgieter T. Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production. Biotechnol Prog 2011, 27:1744-1750. 10.1002/btpr.695, 22002933.
23. Jiang Y, Li F, Button M, Cukan M, Moore R, Sharkey N, Li H. A high-throughput purification of monoclonal antibodies from glycoengineered Pichia pastoris. Protein Expr Purif 2010, 74:9-15. 10.1016/j.pep.2010.04.016, 20447459.
24. Schirrmann T, Al-Halabi L, Dübel S, Hust M. Production systems for recombinant antibodies. Front Biosci 2008, 13:4576-4594.
25. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 2004, 22:1393-1398. 10.1038/nbt1026, 15529164.
26. Jostock T. Expression of antibody in mammalian cells. Antibody Expression and Production 2011, 1-24. Heidelberg: Springer, Al-Rubeai M, [Cell Engineering, vol. 7].
27. Wilke S, Groebe L, Maffenbeier V, Jäger V, Gossen M, Josewski J, Duda A, Polle L, Owens RJ, Wirth D, Heinz DW, van den Heuvel J, Büssow K. Streamlining homogeneous glycoprotein production for biophysical and structural applications by targeted cell line development. PLoS One 2011, 6:e27829. 10.1371/journal.pone.0027829, 3235087, 22174749.
28. Geisse S, Fux C. Recombinant protein production by transient gene transfer into mammalian cells. Meth. Enzymol. 2009, 463:223-238.
29. Baldi L, Hacker DL, Adam M, Wurm FM. Recombinant protein production by large-scale transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol Lett 2007, 29:677-684. 10.1007/s10529-006-9297-y, 17235486.
30. Jostock T, Vanhove M, Brepoels E, Van Gool R, Daukandt M, Wehnert A, Van Hegelsom R, Dransfield D, Sexton D, Devlin M, Ley A, Hoogenboom H, Müllberg J. Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Methods 2004, 289:65-80. 10.1016/j.jim.2004.03.014, 15251413.
31. Geisse S, Henke M. Large-scale transient transfection of mammalian cells: a newly emerging attractive option for recombinant protein production. J Struct Funct Genomics 2005, 6:165-170. 10.1007/s10969-005-2826-4, 16211514.
32. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM. Rational vector design and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1 g/l by transient transfection under serum-free conditions. Nucleic Acids Res 2008, 36:e96. 10.1093/nar/gkn423, 2528171, 18617574.
33. Tuvesson O, Uhe C, Rozkov A, Lüllau E. Development of a generic transient transfection process at 100 L scale. Cytotechnology 2008, 56:123-136. 10.1007/s10616-008-9135-2, 2259262, 19002850.
34. Meissner P, Pick H, Kulangara A, Chatellard P, Friedrich K, Wurm FM. Transient gene expression: recombinant protein production with suspension-adapted HEK293-EBNA cells. Biotechnol Bioeng 2001, 75:197-203. 10.1002/bit.1179, 11536142.
35. Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. PNAS 1995, 92:7297-7301. 10.1073/pnas.92.16.7297, 41326, 7638184.
36. Boussif O, Zanta MA, Behr JP. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther 1996, 3:1074-1080.
37. Thomas M, Klibanov AM. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. PNAS 2002, 99:14640-14645. 10.1073/pnas.192581499, 137472, 12403826.
38. Schirrmann T, Büssow K. Transient production of scFv-Fc fusion proteins in mammalian cells. Antibody Engineering 2010, 387-398. Berlin, Heidelberg: Springer Berlin Heidelberg, Kontermann R, Dübel S.
39. Schlaeger EJ, Christensen K. Transient gene expression in mammalian cells grown in serum-free suspension culture. Cytotechnology 1999, 30:71-83. 10.1023/A:1008000327766, 3449952, 19003357.
40. Wurm F, Bernard A. Large-scale transient expression in mammalian cells for recombinant protein production. Curr Opin Biotechnol 1999, 10:156-159. 10.1016/S0958-1669(99)80027-5, 10209142.
41. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 2002, 30:E9. 10.1093/nar/30.2.e9, 99848, 11788735.
42. Swiech K, Kamen A, Ansorge S, Durocher Y, Picanço-Castro V, Russo-Carbolante EM, Neto MS, Covas DT. Transient transfection of serum-free suspension HEK 293 cell culture for efficient production of human rFVIII. BMC Biotechnol 2011, 11:114. 10.1186/1472-6750-11-114, 3254136, 22115125.
43. Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. PNAS 1999, 96:5177-5181. 10.1073/pnas.96.9.5177, 21837, 10220439.
44. Loignon M, Perret S, Kelly J, Boulais D, Cass B, Bisson L, Afkhamizarreh F, Durocher Y. Stable high volumetric production of glycosylated human recombinant IFNalpha2b in HEK293 cells. BMC Biotechnol 2008, 8:65. 10.1186/1472-6750-8-65, 2538527, 18752669.
45. Zhang J, Liu X, Bell A, To R, Baral TN, Azizi A, Li J, Cass B, Durocher Y. Transient expression and purification of chimeric heavy chain antibodies. Protein Expr Purif 2009, 65:77-82. 10.1016/j.pep.2008.10.011, 19007889.
46. Kozak M. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol 1987, 196:947-950. 10.1016/0022-2836(87)90418-9, 3681984.
47. Kozak M. An analysis of 5′-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987, 15:8125-8148. 10.1093/nar/15.20.8125, 306349, 3313277.
48. Brown CM, Stockwell PA, Trotman CN, Tate WP. Sequence analysis suggests that tetra-nucleotides signal the termination of protein synthesis in eukaryotes. Nucleic Acids Res 1990, 18:6339-6345. 10.1093/nar/18.21.6339, 332501, 2123028.
49. McCaughan KK, Brown CM, Dalphin ME, Berry MJ, Tate WP. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc Natl Acad Sci USA 1995, 92:5431-5435. 10.1073/pnas.92.12.5431, 41708, 7777525.
50. Deb S, DeLucia AL, Baur CP, Koff A, Tegtmeyer P. Domain structure of the simian virus 40 core origin of replication. Mol Cell Biol 1986, 6:1663-1670. 367693, 3023900.
51. Frenzel A, Fröde D, Meyer T, Schirrmann T, Hust M. Generating recombinant antibodies for research, diagnostics and therapy using phage display. Current Biotech 2012, 1:33-41.
52. Pham PL, Kamen A, Durocher Y. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol 2006, 34:225-237. 10.1385/MB:34:2:225, 17172668.
53. Längle-Rouault F, Patzel V, Benavente A, Taillez M, Silvestre N, Bompard A, Sczakiel G, Jacobs E, Rittner K. Up to 100-fold increase of apparent gene expression in the presence of Epstein-Barr virus oriP sequences and EBNA1: implications of the nuclear import of plasmids. J Virol 1998, 72:6181-6185. 110430, 9621086.
54. Li J-H, Chia M, Shi W, Ngo D, Strathdee CA, Huang D, Klamut H, Liu F-F. Tumor-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res 2002, 62:171-178.
55. Zuo Y, Wu J, Xu Z, Yang S, Yan H, Tan L, Meng X, Ying X, Liu R, Kang T, Huang W. Minicircle-oriP-IFNγ: a novel targeted gene therapeutic system for EBV positive human nasopharyngeal carcinoma. PLoS One 2011, 6:e19407. 10.1371/journal.pone.0019407, 3088667, 21573215.
56. Backliwal G, Hildinger M, Kuettel I, Delegrange F, Hacker DL, Wurm FM. Valproic acid: a viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures. Biotechnol Bioeng 2008, 101:182-189. 10.1002/bit.21882, 18454496.
57. Wulhfard S, Baldi L, Hacker DL, Wurm F. Valproic acid enhances recombinant mRNA and protein levels in transiently transfected Chinese hamster ovary cells. J Biotechnol 2010, 148:128-132. 10.1016/j.jbiotec.2010.05.003, 20510314.
58. Lefranc M-P, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, Wu Y, Gemrot E, Brochet X, Lane J, Regnier L, Ehrenmann F, Lefranc G, Duroux P. IMGT(R), the international ImMunoGeneTics information system(R). Nucleic Acids Res 2009, 37:D1006-D1012. 10.1093/nar/gkn838, 2686541, 18978023.
59. Meinke G, Phelan P, Moine S, Bochkareva E, Bochkarev A, Bullock PA, Bohm A. The crystal structure of the SV40 T-antigen origin binding domain in complex with DNA. PLoS Biol 2007, 5:e23. 10.1371/journal.pbio.0050023, 1779811, 17253903.
60. Nagai T, Ibata K, Park ES, Kubota M, Mikoshiba K, Miyawaki A. A variant of yellow fluorescent protein with fast and efficient maturation for cell-biological applications. Nat Biotechnol 2002, 20:87-90. 10.1038/nbt0102-87, 11753368.
61. Rülker T, Meier D, Schirrmann T. Quantification of human IgG and related Fc fusion proteins by a human IgG/Fc capture ELISA. Antibody Engineering 2010, 743-748. Berlin, Heidelberg: Springer Berlin Heidelberg, Kontermann R, Dübel S.